Neisvac-C

Neisseria meningitidis Group C (Strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid A, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It induces active immunity to prevent invasive disease caused by Neisseria meningitidis serogroup C in at‑risk populations.

GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neisvac-C is a conjugate vaccine that targets meningococcal serogroup C infection. It is indicated for: - Invasive meningococcal disease caused by Neisseria meningitidis serogroup C: provides active immunity to prevent infection. - Outbreak control of serogroup C meningococcal disease: helps reduce transmission during epidemic situations. - Travel to regions with high serogroup C prevalence: offers protection for travelers at risk of exposure.

Neisvac-C may cause a range of post‑vaccination reactions. Monitoring and reporting are essential.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild headache within 24 hours.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare demyelinating neuropathy. - Seizures: uncommon neurologic event. - Severe hypotension: marked drop in blood pressure after injection. - Acute allergic reaction: urticaria, angioedema, or bronchospasm.

Before administering Neisvac-C, consider the following safety measures. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: limited data; consult healthcare professional. - Immunocompromised patients: vaccine may elicit a reduced immune response. - Prior allergic reaction to tetanus toxoid or any component: avoid vaccination. - Acute febrile illness: defer vaccination until recovery. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac-C has limited known drug interactions, but caution is advised.

Major Interactions (Avoid): - Immunoglobulin therapy: may diminish vaccine‑induced antibody response. - Live bacterial vaccines administered concurrently: could interfere with immune response.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen): may mask fever post‑vaccination. - Other injectable vaccines given on the same day: consider separate anatomical sites. - Corticosteroids or immunosuppressants: may reduce immunogenicity of the vaccine.